国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (4): 202-208.doi: 10.3760/cma.j.cn371439-20240618-00034

• 论著 • 上一篇    下一篇

基于CT影像加权组学评分构建非小细胞肺癌的免疫治疗疗效预测模型

刘海燕1,2, 张超1,3()   

  1. 1徐州医科大学医学影像学院,徐州 221004
    2徐州医科大学附属沭阳医院影像科,沭阳 223600
    3徐州医科大学附属医院医学影像科,徐州 221004
  • 收稿日期:2024-06-18 修回日期:2024-12-31 出版日期:2025-04-08 发布日期:2025-04-21
  • 通讯作者: 张超,Email:13645214168@163.com
  • 基金资助:
    江苏省卫生健康委员会科研项目(H2023134);江苏省老年健康科研项目(LKM2023014)

A predictive model for immunotherapy efficacy in non-small cell lung cancer constructed based on CT image-weighted radiomics score

Liu Haiyan1,2, Zhang Chao1,3()   

  1. 1School of Medical Imaging,Xuzhou Medical University,Xuzhou 221004,China
    2Department of Imaging,Affiliated Shuyang Hospital of Xuzhou Medical University,Shuyang 223600,China
    3Department of Medical Imaging,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221004,China
  • Received:2024-06-18 Revised:2024-12-31 Online:2025-04-08 Published:2025-04-21
  • Supported by:
    Scientific Research Project of Jiangsu Provincial Health Commission(H2023134);Jiangsu Province Elderly Health Research Project(LKM2023014)

摘要:

目的 基于CT影像加权组学评分构建非小细胞肺癌(NSCLC)的免疫治疗疗效预测模型。方法 选择2021年1月—2023年12月徐州医科大学附属沭阳医院收治的185例接受免疫治疗的NSCLC患者为研究对象,所有患者接受纳武利尤单抗(240 mg)连续治疗3个疗程,并根据实体瘤临床疗效评价标准1.1版评估疗效,根据疗效将患者分为治疗有效组和治疗无效组。基于治疗前动脉期CT图像,采用PyRadiomics工具对所有容积感兴趣区域进行重采样,并进行图像预处理(包括小波变换和拉普拉斯滤波器等方法),提取两组患者的多病灶影像组学特征,并通过Dr.Wise科研平台上对提取的特征进行标准化处理。同时,采用基于注意力机制的多示例学习(a-MIL)算法、最小绝对收缩和选择算子(LASSO)回归、logistic回归构建CT影像加权组学评分模型,并计算每例患者的CT影像加权组学评分。基于R软件(R4.3.3)和rms程序包绘制列线图,同时通过一致性指数(C-index)评估模型的一致性,采用受试者操作特征(ROC)曲线评估列线图模型对NSCLC的免疫治疗疗效预测性能,校准曲线用于评估模型预测概率与实际结果的一致性,决策曲线用于评估模型在不同阈值下的净收益。结果 治疗有效组(66例)与治疗无效组(119例)患者的性别(χ2=3.86,P=0.049)、病理类型(χ2=8.41,P=0.015)、吸烟史(χ2=5.70,P=0.017)、治疗前肺内转移(χ2=5.88,P=0.015)比较,差异均有统计学意义。采用a-MIL算法对多病灶的原始组学特征在病例层面加权求和,共提取342个影像组学特征,其中162个特征一致性较好(组内相关系数>0.80);经方差分析后剔除134个特征,剩余28个特征,经LASSO进行降维后,最终获得7个影像组学特征,分别为GLCMEnergy_angle45_offset、ShortRunEmphasis_angle90_offset1、最大灰度值、Spiculation、GLCMEnergy_angle45_offset7、Sphericity、Vessel。基于上述影像组学特征构建加权组学评分模型为:Radscore=0.624+0.022×GLCMEnergy_angle45_offset-0.227×ShortRunEmphasis_angle90_offset1+0.395×最大灰度值-8.687×Spiculation+0.384×GLCMEnergy_angle45_offset7-0.012×Sphericity-0.284×Vessel。治疗有效组NSCLC患者的CT影像加权组学评分(0.75±0.10)明显高于治疗无效组(0.43±0.14),差异有统计学意义(t=18.00,P<0.001)。ROC曲线分析显示,CT影像加权组学评分预测NSCLC免疫治疗疗效的曲线下面积(AUC)为0.96(95%CI为0.92~0.98),最佳截断值为0.62。多因素分析显示,CT影像加权组学评分≥0.62分(OR=14.77,95%CI为3.25~22.35,P<0.001)、病理类型(鳞状细胞癌)(OR=1.74,95%CI为1.35~3.52,P=0.035)、有吸烟史(OR=4.01,95%CI为1.05~15.30,P=0.042)和治疗前肺内转移(OR=1.20,95%CI为1.01~1.38,P=0.010)均为NSCLC免疫治疗有效的独立预测因素。基于上述4个变量构建预测NSCLC免疫治疗疗效的列线图模型,其模型验证结果显示,C-index为0.96(95%CI为0.93~0.99)。校准曲线分析显示,预测概率与实际概率一致性较好,趋近于理想曲线。ROC曲线分析显示,AUC为0.97(95%CI为0.94~0.99)。决策曲线分析显示,在2%~100%预测范围内,模型净获益。结论 基于CT影像加权组学评分构建预测NSCLC患者免疫治疗疗效的列线图模型,具有较好的预测效能。

关键词: 癌, 非小细胞肺, 免疫疗法, 预测, 影像组学

Abstract:

Objective To construct a predictive model for the efficacy of immunotherapy in non-small cell lung cancer (NSCLC) based on CT image-weighted radiomics score. Methods A total of 185 patients with NSCLC who received immunotherapy in Affiliated Shuyang Hospital of Xuzhou Medical University from January 2021 to December 2023 were selected as the study objects. All patients underwent 3 consecutive cycles of nivolumab (240 mg) treatment,and therapeutic efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1. The patients were divided into treatment-effective group and treatment-ineffective group based on therapeutic outcomes. Based on pre-treatment arterial phase CT images,all volume regions of interest were resampled using PyRadiomics tool,and image preprocessing was performed (including methods such as Wavelet transform and Laplacian filtering). The multi-focal imaging radiomics features of the two groups of patients were extracted,and standardized processing of the extracted features was carried out on the Dr. Wise research platform. At the same time,a CT image-weighted radiomics score model was constructed using an attention-based multi-instance learning (a-MIL) algorithm,the least absolute shrinkage and selection operator (LASSO) regression,and logistic regression,and the CT image-weighted radiomics score of each patient was calculated. The nomogram was plotted using R software (version R4.3.3) and the rms package. The concordance index (C-index) was used to evaluate the concordance of the model. Receiver operator characteristic (ROC) curve was used to evaluate the performance of the nomogram model in predicting immunotherapy efficacy in NSCLC. The calibration curve was used to evaluate the consistency of the predicted probabilities with the actual outcomes,while the decision curve was used to evaluate net benefit of the model across different thresholds. Results There were statistically significant differences in sex (χ²=3.86,P=0.049),pathological type (χ²=8.41,P=0.015),smoking history (χ²=5.70,P=0.017),and pre-treatment pulmonary metastasis (χ²=5.88,P=0.015) between the treatment-effective group (n=66) and treatment-ineffective group (n=119). The original multi-focal radiomics features were weighted and summated by a-MIL algorithm at case level,and a total of 342 imaging radiomics features were extracted,162 features among which had good consistency (intra-class correlation coefficient >0.80). After variance analysis,134 features were eliminated,28 features remained. After dimensionality reduction by LASSO regression,7 imaging radiomics features were obtained. They were GLCMEnergy_angle45_offset,ShortRunEmphasis_angle90_offset1,maximum gray value,Spiculation,GLCMEnergy_angle45_offset7,Sphericity,and Vessel. Based on the above imaging radiomics features,the weighted radiomics score model was constructed as follows:Radscore=0.624+0.022×GLCMEnergy_angle45_offset-0.227×ShortRunEmphasis_angle90_offset1+0.395×maximum gray value-8.687×Spiculation+0.384×GLCMEnergy_angle45_offset7-0.012×Sphericity-0.284×Vessel. The CT image-weighted radiomics score in the treatment-effective group (0.75±0.10) was significantly higher than that in the treatment-ineffective group (0.43±0.14),with a statistically significant difference (t=18.00,P<0.001). ROC curve analysis showed that the area under the curve (AUC) of CT image-weighted radiomics score for predicting immunotherapy efficacy of NSCLC was 0.96 (95%CI:0.92-0.98),and the optimal cutoff value was 0.62. Multivariate analysis showed CT image-weighted radiomics score ≥0.62 (OR=14.77,95%CI:3.25-22.35,P<0.001),pathological type (squamous cell carcinoma) (OR=1.74,95%CI:1.35-3.52,P=0.035),smoking history (OR=4.01,95%CI:1.05-15.30,P=0.042),and pre-treatment pulmonary metastasis (OR=1.20,95%CI:1.01-1.38,P=0.010) were all independent predictors of immunotherapy effectiveness in NSCLC. Based on the above 4 variables,a nomogram model was constructed to predict the immunotherapy efficacy of NSCLC,and the model validation results showed that the C-index was 0.96 (95%CI:0.93-0.99). Calibration curve analysis showed good consistency of the predicted probabilities with the actual probabilities,closely aligning with the ideal curve. ROC curve analysis showed that AUC was 0.97 (95%CI:0.94-0.99). Decision curve analysis showed that the model had a net benefit within the prediction range of 2% to 100%. Conclusion The nomogram model based on CT image-weighted radiomics score is effective in predicting immunotherapy efficacy of NSCLC patients.

Key words: Carcinoma, non-small-cell lung, Immunotherapy, Forecasting, Radiomics